Guardant Health, Inc.(GH)Company Profile & BusinessNASDAQ
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults.
In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Guardant Health, Inc. (GH) between Jul 17, 2025 and Sep 21, 2026 consists of 232 total transactions. Among these, company executives and board members conducted 207 buys (totaling 3,212,081 shares) and 25 sells (totaling 182,755 shares). This activity resulted in a net change of 3,029,326 shares, reflecting net buying interest with an estimated net acquisitions value of $183.43M.
232 insider transactions found. Showing 10 of 232 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| MIGNONE ROBERTO A. | Director | 264 | N/A | Sep 21, 2026 |
| HIDALGO MEDINA MANUEL | Director | 232 | N/A | Sep 17, 2026 |
| Krognes Steve E. | Director | -3,300 | $175.42 | Sep 16, 2026 |
| Krognes Steve E. | Director | -971 | $177.48 | Sep 16, 2026 |
| Azar Alex M II | Director | -826 | $175.00 | Sep 16, 2026 |
| AZAR ALEX M II | Director | 826 | $0.14 | Sep 16, 2026 |
| TARIQ MUSA | Director | 116 | $20300.00 | Sep 16, 2026 |
| KROGNES STEVE E | Director | 6,674 | $1.17 | Sep 16, 2026 |
| Krognes Steve E. | Director | -1,103 | $174.46 | Sep 16, 2026 |
| Krognes Steve E. | Director | -1,300 | $176.34 | Sep 16, 2026 |
Explore More Analysis for GH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.